An open label, randomized, single dose, two-sequence, two-treatment, four-period, fully replicate, cross-over pharmacokinetic study comparing Alverine citrate/Simeticone 60 mg/300 mg soft capsules to Meteospasmyl 60 mg/300 mg soft capsules in healthy male and female subjects under fed conditions.

2024-516942-21-00 Protocol 845900241/0147/1 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 21 Oct 2024 · End 6 Dec 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 845900241/0147/1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 36
Countries 1
Sites 1

Not applicable (submitted trial is a bioavailability study in healthy subjects)

Key facts

Sponsor
Zaklady Farmaceutyczne Polpharma S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
21 Oct 2024 → 6 Dec 2024
Decision date (initial)
2024-09-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Not applicable (submitted trial is a bioavailability study in healthy subjects)

VersionLevelCodeTermSystem organ class
20.0 HLT 10016770 Flatulence bloating and distension 10017947
20.0 PT 10016766 Flatulence 100000004856

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Zaklady Farmaceutyczne Polpharma S.A.

Sponsor organisation
Zaklady Farmaceutyczne Polpharma S.A.
Address
Ul. Pelplinska 19
City
Starogard Gdanski
Postcode
83-200
Country
Poland

Scientific contact point

Organisation
Zaklady Farmaceutyczne Polpharma S.A.
Contact name
Clinical R&D

Public contact point

Organisation
Zaklady Farmaceutyczne Polpharma S.A.
Contact name
Clinical R&D

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 36 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinic, Umelecka 305/1, Moravska Ostrava, Moravska Ostrava A Privoz

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-10-21 2024-12-06 2024-10-21 2024-11-09

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-21 Czechia Acceptable
2024-09-13
2024-09-13
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-09-24 Czechia Acceptable
2024-09-13
2024-09-24
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-11-06 Czechia Acceptable
2024-09-13
2024-11-06